Lynch Receives Bristol-Myers Squibb Award
NEW YORK--Henry T. Lynch, MD, whose pioneering work during the 1960s and '70s helped establish the hereditary basis of certain gastrointestinal, breast, and ovarian cancers, is the recipient of the 19th annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research. Thanks in large part to Dr. Lynch, the specific genetic mutations responsible for a number of familial cancers have been identified.
NEW YORK--Henry T. Lynch, MD, whose pioneering work during the1960s and '70s helped establish the hereditary basis of certaingastrointestinal, breast, and ovarian cancers, is the recipientof the 19th annual Bristol-Myers Squibb Award for DistinguishedAchievement in Cancer Research. Thanks in large part to Dr. Lynch,the specific genetic mutations responsible for a number of familialcancers have been identified.
Dr. Lynch is professor of medicine and chairman of preventivemedicine and public health, Creighton University School of Medicine,Omaha.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
